About: SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien
Creator	Krüger, · Rheumatol, Z Specker, · Hoyer, · Iking-Konert, · Leipe, J Schulze-Koops, ·
Source	Medline; PMC
abstract	The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV‑2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs.
has issue date	2020-08-26(xsd:dateTime)
bibo:doi	10.1007/s00393-020-00878-0
bibo:pmid	32845393
has license	cc-by
sha1sum (hex)	64ecf0caae01ab9e34a4bbf6cfc47b9c24394b42
schema:url	https://doi.org/10.1007/s00393-020-00878-0
resource representing a document's title	SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien
has PubMed Central identifier	PMC7448266
has PubMed identifier	32845393
schema:publication	Z Rheumatol
resource representing a document's body	covid:64ecf0caae01ab9e34a4bbf6cfc47b9c24394b42#body_text
is schema:about of	named entity 'COVID-19' named entity 'Ein' named entity 'SARS-CoV-2' named entity 'antirheumatic' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'rheumatic diseases' named entity 'antirheumatic' named entity 'COVID-19' named entity 'COVID-19 pandemic' named entity 'SARS-CoV-2' named entity 'Creative Commons' named entity 'momentane' named entity 'EULAR' named entity 'COVID-19' named entity 'EULAR' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'momentane' named entity 'COVID-19' named entity 'antirheumatic' named entity 'rheumatic diseases' named entity 'risk assessment' named entity 'im Juli' named entity 'EULAR' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'Immunsuppression' named entity 'oder' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'risk assessment' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'DMARDs' named entity 'American College of Rheumatology' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-COV-2' named entity 'Rheuma' named entity 'mit' named entity 'DER' named entity 'HOT' named entity 'UND' named entity 'EIN' named entity 'SARS-CoV-2' named entity 'BCR' named entity 'MIT'
is part of of	SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV‑2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs. covid:64ecf0caae01ab9e34a4bbf6cfc47b9c24394b42#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software